Biological

assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.

assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria. is a biological therapy with 1 clinical trials. Currently 1 active trials ongoing.

Find Trials

Total Trials

Max Phase

—

Type

BIOLOGICAL

Molecule

—

Success Metrics

Active Trials

1(100%)

Phase Distribution

Ph not_applicable

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

N/ANon-phased studies

1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Detailed Status

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

recruiting1100%

Recent Activity

1 active trials

Showing 1 of 1

recruitingnot_applicable

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

NCT04790682

Clinical Trials (1)

Showing 1 of 1 trials

NCT04790682Not Applicable

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

Recruiting

All 1 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 1